for the antigen by filing with the antigen as is described in u s pat application ser no 08 005 008 filed jan 15 1993 entitled method of inhibiting viral reproduction of which this application is a continuation in part in this embodiment when the antigen there an enveloped virus is mixed with the paucilamellar lipid vesicles the virus and adjuvant fuse denaturing the nucleic acid and inactivating the virus the inactivated virus adjuvant hybrid is then useful as a vaccine moreover the vesicle can serve to carry additional adjuvants within the central cavity or between the bilayers an adjuvanted vaccine containing the antigen influenza a h 3 n 2 beijing was prepared using nonphospholipid paucilamellar lipid vesicles as adjuvants adjuvanticity of the two formulations namely non specific immune stimulator and carrier adjuvant formulations was compared using the mean ifa of each composition as compared with that of the antigen alone as shown in fig1 adjuvant formulations were prepared using an automated syringe machine specifically a 5cc syringe machine the adjuvant could also be made according to the general procedure set forth in u s pat no 4 911 928 briefly the lipid components of the vesicle walls were heated to a flowable state and placed in a first component of the syringe machine the aqueous component in this case containing the antigen fluzone u2122 see below was heated and placed in a second.